Provided by Tiger Trade Technology Pte. Ltd.

Taysha Gene Therapies, Inc.

5.16
-0.1800-3.37%
Post-market: 5.160.00000.00%19:30 EDT
Volume:2.40M
Turnover:12.32M
Market Cap:1.68B
PE:-12.51
High:5.24
Open:5.24
Low:5.01
Close:5.34
52wk High:7.30
52wk Low:2.71
Shares:325.83M
Float Shares:233.00M
Volume Ratio:1.20
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4126
EPS(LYR):-0.3409
ROE:-47.05%
ROA:-23.82%
PB:4.34
PE(LYR):-15.14

Loading ...

Taysha Gene Therapies Q2 EPS USD -0.13

THOMSON REUTERS
·
Aug 12

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Aug 12

Taysha Gene Therapies Grants New Hire 144,000 RSUs, 92,400 Stock Options Priced at $5.78

Reuters
·
Aug 07

Taysha Gene Therapies Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 07

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 07

Taysha Gene Therapies to Report Q2 Results, Host Corporate Update Call and Webcast

Reuters
·
Aug 05

Taysha Gene Therapies Taps Catalent for TSHA-102 Rett Syndrome Commercial Manufacturing Support

Reuters
·
Aug 03

Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of Tsha-102 Gene Therapy for Rett Syndrome

THOMSON REUTERS
·
Aug 03

Taysha Gene Therapies Posts Corporate Deck Highlighting Tsha-102 Gene Therapy Program for Rett Syndrome

Reuters
·
Jul 25

Taysha Gene Therapies is Maintained at Buy by Goldman Sachs

Dow Jones
·
Jul 21

Taysha Gene Therapies falls -11.0%

TIPRANKS
·
Jul 14

Taysha Gene Therapies President, Head of R&D Sukumar Nagendran Disposes of 200,000 Common Shares for $1.25 Million

Reuters
·
Jul 11

Taysha Gene Therapies (TSHA) Could Be 49% Below Fair Value After Russell Index Drop

Simply Wall St.
·
Jul 10

Taysha Gene Therapies Price Target Maintained with a $11.00/share by Citizens

Dow Jones
·
Jul 02

Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX), Taysha Gene Therapies (TSHA) and Zymeworks (ZYME)

TIPRANKS
·
Jul 01

Taysha Gene Therapies is Maintained at Outperform by Baird

Dow Jones
·
Jun 30

Analysts Offer Insights on Healthcare Companies: HeartFlow, Inc. (HTFL), Taysha Gene Therapies (TSHA) and Abivax SA Sponsored ADR (ABVX)

TIPRANKS
·
Jun 30

Taysha Gene Therapies Posts Reveal Part a Phase 1/2 Tsha-102 Rett Syndrome Trial Presentation

Reuters
·
Jun 29

Taysha Gene Therapies Announces Major Equity Financing Deal

TIPRANKS
·
Jun 26

Taysha Gene Therapies Announces Multiple Presentations Highlighting Its Tsha-102 Clinical Program at the 2026 Irsf Rett Syndrome Scientific Meeting

THOMSON REUTERS
·
Jun 26